Publications
A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth. Genes Dev. 2015;29(5):483-8.
. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. Cancer Res. 2015;75(15):3127-38.
. . Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 2014;4(2):166-74.
. From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discov. 2014;4(5):516-8.
. Intratumor heterogeneity alters most effective drugs in designed combinations. Proc Natl Acad Sci U S A. 2014;111(29):10773-8.
. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A. 2013;110(2):E170-9.
. Integrated network analyses for functional genomic studies in cancer. Semin Cancer Biol. 2013;23(4):213-8.
. Predicting cancer drug mechanisms of action using molecular network signatures. Mol Biosyst. 2013;9(7):1604-19.
. Understanding resistance to combination chemotherapy. Drug Resist Updat. 2012;15(5-6):249-57.
. Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. Cancer Res. 2011;71(17):5850-8.
. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol. 2011;7(2):92-100.
. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009;23(16):1895-909.
. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle. 2009;8(19):3112-9.
. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet. 2009;41(10):1133-7.
. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol Cancer Ther. 2009;8(8):2183-92.
.